Arcadia Biosciences, Inc.
RKDA
$0.92
-$0.11-10.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.10M | 901.00K | 1.30M | 1.46M | 1.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.10M | 901.00K | 1.30M | 1.46M | 1.20M |
| Cost of Revenue | 700.00K | 709.00K | 884.00K | 833.00K | 682.00K |
| Gross Profit | 400.00K | 192.00K | 418.00K | 622.00K | 518.00K |
| SG&A Expenses | 1.18M | 1.57M | 1.57M | 2.12M | 1.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.88M | 2.28M | 2.45M | 2.96M | 2.42M |
| Operating Income | -779.00K | -1.38M | -1.15M | -1.50M | -1.22M |
| Income Before Tax | -4.39M | -1.33M | 856.00K | -4.46M | 2.60M |
| Income Tax Expenses | -- | 8.00K | -- | -- | -- |
| Earnings from Continuing Operations | -4.39M | -1.34M | 856.00K | -4.46M | 2.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.39M | -1.34M | 856.00K | -4.46M | 2.60M |
| EBIT | -779.00K | -1.38M | -1.15M | -1.50M | -1.22M |
| EBITDA | -771.00K | -1.37M | -1.15M | -1.49M | -1.21M |
| EPS Basic | -2.11 | -0.97 | 0.63 | -3.26 | 1.90 |
| Normalized Basic EPS | -0.85 | -0.61 | 0.39 | -2.50 | 0.39 |
| EPS Diluted | -2.11 | -0.98 | 0.62 | -3.26 | 1.90 |
| Normalized Diluted EPS | -0.85 | -0.61 | 0.39 | -1.31 | 0.39 |
| Average Basic Shares Outstanding | 2.08M | 1.37M | 1.37M | 1.37M | 1.37M |
| Average Diluted Shares Outstanding | 2.08M | 1.37M | 1.37M | 2.60M | 1.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |